Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Cash from Operations (2016 - 2025)

Integra Lifesciences Holdings (IART) has disclosed Cash from Operations for 17 consecutive years, with 11816000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations fell 76.71% to 11816000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 50384000.0 through Dec 2025, down 61.06% year-over-year, with the annual reading at 50384000.0 for FY2025, 61.06% down from the prior year.
  • Cash from Operations hit 11816000.0 in Q4 2025 for Integra Lifesciences Holdings, down from 40906000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 91290000.0 in Q2 2021 to a low of 11257000.0 in Q1 2025.
  • Historically, Cash from Operations has averaged 44830850.0 across 5 years, with a median of 42625000.0 in 2022.
  • Biggest five-year swings in Cash from Operations: surged 231.9% in 2021 and later plummeted 171.45% in 2025.
  • Year by year, Cash from Operations stood at 69277000.0 in 2021, then rose by 23.18% to 85334000.0 in 2022, then tumbled by 31.15% to 58750000.0 in 2023, then fell by 13.63% to 50740000.0 in 2024, then tumbled by 76.71% to 11816000.0 in 2025.
  • Business Quant data shows Cash from Operations for IART at 11816000.0 in Q4 2025, 40906000.0 in Q3 2025, and 8919000.0 in Q2 2025.